Loss of a gp130 Cardiac Muscle Cell Survival Pathway Is a Critical Event in the Onset of Heart Failure during Biomechanical Stress  by Hirota, Hisao et al.
Cell, Vol. 97, 189±198, April 16, 1999, Copyright 1999 by Cell Press
Loss of a gp130 Cardiac Muscle Cell Survival
Pathway Is a Critical Event in the Onset
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transducer gp130 display embryonic lethality and de-University of California, San Diego
fects in diverse embryonic compartments (Yoshida etLa Jolla, California 92093
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Ware et al., 1995). Unfortunately, given the pleiotropic
effects of the IL-6 family on multiple tissues, and the
genetic ablation of these widely expressed components
Summary of the cytokine signaling pathway in virtually every cell
type, it is often difficult to conclude from these studies
Biomechanical stress is a major stimulus for cardiac whether these defects arise as a result of a primary or
hypertrophy and the transition to heart failure. By secondary requirement for a specific cytokine signaling
generating mice that harbor a ventricular restricted pathway.
knockout of the gp130 cytokine receptor via Cre-loxP- Recently, this point has become of particular impor-
mediated recombination, we demonstrate a critical tance in elucidating the specific role of the IL-6-related
role for a gp130-dependent myocyte survival pathway cytokines in the pathogenesis of cardiac failure, the lead-
in the transition to heart failure. Such conditional mu- ing cause of combined morbidity and mortality in the U.S.
tant mice have normal cardiac structure and function, and other developed nations. In response to chronic
but during aortic pressure overload, these mice dis- increases in hemodynamic pressure (e.g., long-standing
play rapid onset of dilated cardiomyopathy and mas- hypertension) and volume overload (e.g., postmyocar-
sive induction of myocyte apoptosis versus the control dial injury), the heart initiates an adaptive response of
mice that exhibit compensatory hypertrophy. Thus, compensatory hypertrophy that leads to cardiac en-
cardiac myocyte apoptosis is a critical point in the largement and a maintenance of normal cardiac func-
transition between compensatory cardiac hypertro- tion. However, there can be a temporal transition under
phy and heart failure. gp130-dependent cytokines may conditions of chronic stimulation where these biome-
represent a novel therapeutic strategy for preventing chanical stimuli subsequently activate pathways that
in vivo heart failure. lead to cardiac muscle cell dysfunction, myocyte loss,
replacement fibrosis, and overt congestive heart failure
(for a review, see Chien et al., 1998). A growing body ofIntroduction
evidence suggests the possibility that cytokines which
operate via gp130 pathways might play a critical role inCytokines play a critical role in the control and mainte-
the onset of cardiac failure (for a review, see Wollertnance of signaling pathways that regulate mammalian
and Chien, 1997). Previous studies coupling an in vitrophysiology in multiple organ systems. Their widespread
embryonic stem cell model of cardiogenesis (Robbinsimportance is reflected in the extensive tissue distribu-
et al., 1990; Miller-Hance et al., 1993) and expressiontion of the cytokine network, their pleiotropic effects in
cloning with a high-throughput cardiac myocyte hyper-the in vivo setting, the existence of conserved pathways
trophy assay system (Shubeita et al., 1990; Pennica etof signal transduction, and a large degree of functional
al., 1995) resulted in the isolation of a new member of theredundancy in a variety of organ systems (reviewed in
IL-6 cytokine family, CT-1 (Pennica et al., 1995; Sheng etKishimoto et al., 1994; Taga and Kishimoto, 1997). For
al., 1996; Wollert et al., 1996). CT-1 can activate severalexample, mice that harbor a complete deficiency in indi-
features of myocyte hypertrophy in vitro, including cellvidual members of the interleukin 6 (IL-6) family of cyto-
enlargement without proliferation, sarcomeric organiza-kines (IL-6, leukemia inhibitory factor [LIF], ciliary neuro-
tion, and embryonic gene expression. In addition, CT-1trophic factor [CNTF], or IL-11 receptor a) or their
is a potent myocyte survival factor for differentiateddownstream gp130-dependent signaling components
cardiac muscle cells (Sheng et al., 1997) and is capablecan display multiple organ defects, including disorders
of blocking the onset of cardiomyocyte apoptosis fol-
lowing serum deprivation (Sheng et al., 1997). Recent
findings indicate that the widespread, constitutive ex-‖ To whom correspondence should be addressed (e-mail: kchien@
pression of gp130 in transgenic mice can lead to cardiacucsd.edu).
hypertrophy (Hirota et al., 1995). In addition, embryonic# Present address: Pharma Research Antiinfectives, Bayer AG, Wup-
pertal, Germany. cardiac defects are seen in completely deficient gp130
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mutant embryos that likely lead to early lethality (Yo- in tail DNA, demonstrating tissue specificity of the floxed
out allele. To demonstrate that a deficiency in gp130shida et al., 1996). However, these studies do not neces-
sarily reflect the normal, primary effect of gp130 on in had been established, we directly examined the level of
gp130 by quantitative Western blotting; the immunoblotvivo cardiac function, given that the nature of the genetic
manipulation was not restricted to the cardiac compart- (shown in Figure 1C) was probed with an antibody to
gp130, thereby documenting the reduction of the gp130ment, and other noncardiac defects were present in
each case. protein (60%) exclusively in the heart of GP CKO mice,
with no detectable decrease in the liver. In addition,Using Cre-lox technology to achieve a ventricular
chamber±restricted knockout of the gp130 cytokine re- there was almost no difference in cardiac levels of gp130
in studies of other genotypes, using gp130flox/1,ceptor, we now provide unequivocal evidence for a criti-
cal role of a gp130-dependent myocyte survival path- MLC2vCreKI/1 (CNT) as a control. When cardiomyo-
cytes were isolated as a partially purified single cellway. These studies identify cardiac myocyte apoptosis
as a critical point in the transition between compensa- preparation, the ratio of the gp130 protein level in cardio-
myocytes from GP CKO versus CNT mice was approxi-tory cardiac hypertrophy and heart failure and suggest
that ligands operating via gp130 may represent a novel mately 20% (Figure 1D), indicating that there was at least
an 80% decrease in gp130 protein levels in ventriculartherapeutic strategy for preventing heart failure in the
in vivo context. This study represents clear evidence that muscle cells. In Figure 1C and 1D, the expression of
STAT3 was comparable between these groups, therebypromoting cardiac myocyte survival is a critical event in
the transition between compensatory hypertrophy and demonstrating specificity of the gp130 decrease.
the onset of heart failure in the in vivo context.
The Requirement for gp130 during Cardiac
Development Is Non±CardiacResults
Muscle Autonomous
Surprisingly, GP CKO mice have normal embryonic via-Generation of Ventricular Muscle±Specific
bility without evidence of any of the cardiac morpho-gp130 Knockout Mice
genic defects observed in the complete gp130-deficientTo generate mice that harbor a ventricle chamber re-
embryos (Yoshida et al., 1996) and the mice with postna-stricted knockout of the gp130 gene, we utilized Cre-
tally inactivated gp130 (Betz et al., 1998). Pups of GPlox strategies, employing gp130 floxed allele mice (Betz
CKO mice were born normally and externally indistin-et al., 1998). This floxed gp130 allele contains two loxP
guishable from littermates of other genotypes. The GPsites that have been introduced into exon 16, which
CKO mice were recovered at Mendelian frequency andencodes the transmembrane domain of gp130 (desig-
grew to adulthood. Histological examination of GP CKOnated ªgp130floxº) (Betz et al., 1998) (Figure 1A). Follow-
hearts at 8 weeks revealed no evidence of necrosis,ing the delivery of Cre, this critical exon is excised,
ventricular fibrosis, or myofibrillar disarray (data notleading to the loss of gp130 from the plasma membrane,
shown). In addition, sensitive genetic markers of cardiacresulting in a complete lack of responsiveness to gp130-
injury/hypertophy, such as atrial and brain natriureticrelated cytokines. To mutate this allele exclusively in
peptide (Chien et al., 1991), were not induced. Takenventricular muscle cell lineages, we have employed a
together, these results indicate that during normal em-knock-in (KI) strategy and homologous recombination
bryonic development, there is no cardiac myocyte cell±to insert Cre coding sequences into the genomic locus
autonomous requirement for the gp130 signaling path-of the myosin light chain 2v (MLC2v) gene (designated
way. Thus, the cardiac defect seen in conventionalªMLC2vCreKIº) (Chen et al., 1998a, 1998b), which is the
gp130 knockout embryos represents a secondary effectearliest ventricular-restricted marker during mammalian
of gp130 deficiency that may arise as a consequencecardiogenesis (O'Brien et al., 1993; Ross et al., 1996). We
of the severe hematopoietic defects and subsequenthave previously reported that matings between these
effects on the oxygenation status of the mutant embryo;MLC2v Cre knock-in mice and an RXRa floxed allele can
or the deletion of gp130 in other cell types in the heartgenerate a high-efficiency cardiac ventricular muscle
may lead to the phenotype in the heart.knockout at E8.75 with no detectable effect on atrial
muscle. The generation and characteristics of the
MLC2v knock-in mice have been previously described Cardiac Function of GP CKO Mice
To investigate whether the cardiac-specific knockout ofin detail elsewhere (Chen et al., 1998a, 1998b).
Accordingly, we bred gp130flox/flox:MLC2v1/1 and gp130 would affect in vivo cardiac function, we utilized
a panel of in vivo miniaturized physiological technologygp130flox/1:MLC2vCreKI/1 mice, resulting in gp130flox/
flox:MLC2vKI/1 mice, which harbor a ventricle-specific (Kubalak et al., 1996), including echocardiography (Ta-
naka et al., 1996) and cardiac catheterization (Palakodetigp130 knockout (GP CKO). Adult ventricular tissue and
tails from GP CKO mice were extracted and genomic et al., 1997) in anesthetized mice. As revealed by the
echocardiography of multiple littermates, there was noDNA digested and probed to visualize the nonrecom-
bined floxed allele and the recombined floxed-out allele. difference in left ventricle (LV) end-diastolic (LVEDD),
end-systolic dimension (LVESD), fractional shorteningTo assess the efficiency of Cre recombination in ventric-
ular muscle, we purified ventricular myocytes from GP (%FS), septal wall thickness, and posterior wall thick-
ness between GP CKO and CNT mice at baseline (TableCKO mice. As shown in Figure 1B, 70% of the alleles in
the heart from GP CKO mice have undergone recombi- 1). Thus global cardiac structure and function was nor-
mal. Furthermore, while hemodynamic data revealednation, while no evidence of the floxed out allele is found
GP130 Myocyte Survival Pathways and Heart Failure
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Figure 1. Outline of the Strategy Used to Generate a Ventricular Chamber Restricted Mutation in the gp130 Gene
(A) Schematic representation of exon structures in the part of the gp130 gene encoding the transmembrane domain (exon 16). Targeting
vector and mutant gp130 gene are shown. The closed box (probe) corresponds to the sequence used for Southern hybridizaion in (B). Exon
numbers are indicated.
(B) Southern genotype analysis. The Southern blot, carrying adult mouse tail and ventricle DNA digested with EcoRI, hybridized with a probe
that discriminates between the floxed, floxed out, and wild-type allele. The genotypes for the samples are gp130flox/1, MLC2vCreKI/1, tail
(lane 1), gp130flox/flox, MLC2vCreKI/1, tail (lane 2), gp130flox/1, MLC2vCreKI/1, heart (lane 3), and gp130flox/flox, MLC2vCreKI/1, heart
(lane 4). The position of the bands representing the gp1301 (wild-type), gp130flox (floxed allele), and gp130delta (floxed-out allele ) alleles are
shown.
(C) Expression of gp130 protein and STAT3 were determined by protein immunoblot analysis of myocardial extracts from gp1301/1, MLC2v1/1,
heart (line 1), gp130flox/1, MLC2v1/1, heart (line 2), gp130flox/flox, MLC2v1/1, heart (line 3), gp130flox/1, MLC2vKICre/1, heart (line 4),
gp130flox/flox, MLC2vKICre/1, heart (line 5), and gp130flox/flox, MLC2vKICre/1, liver (line 6).
(D) Expression of both gp130 and STAT3 proteins were determined by immunoblot analysis of myocardial enriched extracts (M) and nonmyocyte
extracts (NM) from control (CNT) and GP CKO hearts. Data are representative of two independent experiments with nearly identical results.
that LV contractility (assessed by LV dp/dtmax) and dia- of the CNT mice, this decrease was not significant as
assessed by one-way ANOVA statistical analysis andstolic function (assessed by LV dp/dtmin) at baseline in
GP CKO tended toward a decrease compared to that is within the margin of error noted for other naturally
Table 1. Analysis of In Vivo Cardiac Size and Function by Echocardiography in GP CKO at Basal Level and 2 Days after Transaortic
Constriction (TAC)
CNT Basal CNT after TAC GP CKO Basal GP CKO after TAC
(n 5 6) (n 5 6) (n 5 7) (n 5 7)
LVEDD (mm) 3.57 6 0.23 3.37 6 0.61 3.31 6 0.36 3.76 6 0.26
LVESD (mm) 2.31 6 0.18 2.28 6 0.48 2.08 6 0.39 2.91 6 0.48c
FS (%) 35.2 6 3.02 32.58 6 3.18 35.25 6 3.02 22.67 6 6.35a,b
SEPth (mm) 0.69 6 0.08 0.76 6 0.16 0.6 6 0.11 0.69 6 0.1
PWth (mm) 0.67 6 0.03 0.71 6 0.16 0.67 6 0.13 0.65 6 0.06
HR (beat/min) 504 6 77 440 6 88 417 6 63 473 6 127
Mean Vcf (circ/s) 5.9 6 1.27 5.92 6 0.87 7.31 6 1.38 3.83 6 1.68a
BW (g) 25.5 6 4.2 23.5 6 4.4 24.7 6 4.8 21.3 6 4.8
Mean age at echo (weeks) 7.5 6 0.84 7.5 6 0.84 7.71 6 0.49 7.71 6 0.49
LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension; HR, heart rate; FS, percent fractional shortening
calculated as (LVEDD-LVESD)/LVEDD 3 100; SEPth, septal wall thickness; PWth, posterior wall thickness; mean Vcf, mean velocity of
circumferential fiber shortening; BW, body weight.
a p , 0.001, GP CKO after TAC versus GP CKO basal and CNT basal.
b p , 0.01, GP CKO after TAC versus CNT after TAC.
c p , 0.01, GP CKO after TAC versus GP CKO basal.
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Figure 2. Hemodynamic Data in GP CKO
Retrograde cardiac catheterization at the left ventricle via the carotid artery was performed in intact anesthetized mice using a 1.4 Fr. high-
fidelity micromanometer. Parameters are shown at baseline and after progressive infusion of dobutamine in GP CKO (squares; n 5 8) and
CNT (circles; n 5 8) mice. HR, heart rate; LV dp/dtmax, maximal first derivative of LV pressure; LV dp/dtmin, minimal first derivative of LV
pressure; *, p , 0.05, **, p , 0.01, ***, p , 0.001, GP CKO versus CNT.
occurring and mutant mice without overt cardiac dys- after TAC (Table 1). At this early time point, cardiac
contractility was significantly depressed in GP CKOfunction. A normal response to dobutamine was also
observed, again consistent with preserved cardiac func- mice (p , 0.001), as assessed by fractional shortening
and shortening velocity. Although wall thickness andtion, as suggested by the normal echocardiogram (Fig-
ure 2). Finally, the GP CKO mice did not display any LVEDD were similar to control levels, LVESD signifi-
cantly increased in GP CKO mice versus control, sug-gross hypertrophy or heart failure phenotype up to six
months of age. Taken together, these findings indicated gesting the rapid onset of chamber dysfunction and
dilation. Strikingly, 7 days after TAC, GP CKO mice dis-that the GP CKO mice display global cardiac structure
and function within normal limits and that the partial loss played a significantly increased mortality as compared
with CNT mice with over 90% of the GP CKO mice dyingof gp130 does not by itself lead to cardiac hypertrophy or
a heart failure phenotype. by 7 days after TAC, whereas 70% of the CNT mice
remained alive at this time (p , 0.001) (Figure 4A). Histo-
logical examination of the heart demonstrated ventricu-A gp130-Dependent Pathway Is Required
lar enlargement involving both the left and right cardiacfor Adaptive Compensatory Hypertrophy
chamber in the gp130-deficient hearts (Figure 4B), pro-during Biomechanical Stress
viding additional evidence for the rapid onset of a pheno-of Pressure Overload
type consistent with dilated cardiomyopathy, as seenTo determine whether gp130 signaling is activated dur-
in the clinical setting and in analogous mouse modeling the biomechanical stress response, we utilized a
microsurgical approach to induce cardiac hypertrophy
in vivo by pressure overload following transverse aortic
constriction (TAC) (Rockman et al., 1991). Subsequently,
we performed Western blotting analysis to quantitate
the extent of tyrosine phosphorylation of STAT3, a
downstream molecule of gp130 activation. At various
time points after TAC, the left ventricles were excised
from GP CKO and CNT mice. In the left ventricle of CNT
mice, STAT3 was phosphorylated within 48 hr following
TAC, which was maintained for the entire 7-day period.
However, little or no phosphorylation of STAT3 was ob-
served in GP CKO mice following TAC (Figure 3). Thus,
the activation of STAT3, a downstream event in the
gp130 pathway, occurs early following delivery of the
biomechanical stimulus of pressure overload. GP CKO
mice display a loss of this STAT3 activation, demonstrat-
Figure 3. Effect of Pressure Overload on Tyrosine Phosphorylationing the functional effect of the gp130 conditional knock-
of STAT3 in CNT (A) and GP CKO (B) Mouse Heartsout. Thus, biomechanical stress induced the activation
Protein extracts from hearts of each group were examined at eachof gp130 and the downstream STAT3 pathway in cardiac
point (0, 3 hr, 2 days, 4 days, and 6 days after TAC) were immunoblot-myocytes in the in vivo setting of pressure overload that
ted with anti-phospho-STAT3 and STAT3 antibody. Protein extractwas lost in GP CKO mice.
from the CNT heart 2 days after TAC [2d(CNT)] was used as a
The in vivo physiological consequences of the loss of positive control in the Western blotting of GP CKO heart extracts
the stress-activated gp130 pathway in GP CKO mice (B). Data are representative of two independent experiments with
nearly identical results.was assessed in vivo using echocardiography 2 days
GP130 Myocyte Survival Pathways and Heart Failure
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Figure 4. Phenotypic Effects of Biomechanical Stress on GP130 Conditional KO Mice
(A) Survival analysis of gp130 conditional KO mice after TAC. Each group started with 15 (CNT with TAC, diamonds), 21 (GP CKO with TAC,
circles), 3 (CNT with sham-operation, squares) and 3 (GP CKO with sham-operation, triangles) mice. Differences in survival rates between the
CNT and GP CKO groups after TAC were significant by Peto-Peto-Wilcoxon test (*, p , 0.001).
(B) Pathological analysis of the gp130 conditional KO hearts. Histological sections of hearts from 3 days and 7 days after TAC in CNT and
GP CKO mice. Heart were fixed in 4% paraformaldehyde and stained with hematoxylin and eosin. Data are representative of three independent
experiments with nearly identical results.
(C) Pattern of cardiac gene expression in GP CKO and CNT mice following TAC. Total RNA (10 mg) was isolated from the left ventricle of GP
CKO and CNT hearts 3 days after sham-operation or TAC. Northern blot were generated and probed with mouse c-fos (1.2 kb fragment) (Van
Beveren et al., 1983), mouse BNP cDNA (full-length cDNA), rat SERCA2a, rabbit Ryr, mouse Pln, and rat iNOS, which was prepared by reverse
transcriptase±polymerase chain reaction (Balligand et al., 1994). Human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (1.2 kbp cDNA)
(Adams et al., 1992) was used to control for loading and transfer efficiency. Probes for SERCA, Ryr, and Pln were generous gift from Dr. W. H.
Dillmann. Data are representative of three independent experiments with nearly identical results.
systems (Arber et al., 1997). In contrast, control mice program and suggest that the rapid onset of chamber
dilation and dysfunction may not be secondary to thedeveloped concentric hypertrophy and maintained a
normal chamber volume consistent with an adaptive loss of the ability to activate a hypertrophic response.
We also considered the possibility that GP CKO micephysiological response (Figure 4B).
might have abnormalities in contractile protein expres-
sion in the heart. However, no significant abnormalitiesgp130-Deficient Hearts Display a Normal Induction
of the Embryonic Gene Program during the in contractile protein expression were detected by SDS-
PAGE analysis of ventricular protein derived from theBiomechanical Stress of Pressure Overload
To further explore the mechanism of the functional car- GP CKO versus control animals (data not shown).
diac deterioration, the pattern of myocardial gene ex-
pression was characterized in pressure-overloaded GP The Loss of the Stress-Activated gp130 Pathway
Leads to Massive Cardiac Myocyte ApoptosisCKO mice. Human heart failure and physiologically rele-
vant experiment models of murine cardiac hypertrophy following the Biomechanical Stress
of Pressure Overloadexhibit increased expression of immediate early genes,
embryonic markers, and a panel of genes that encode As noted earlier, gp130-dependent agonists such as
CT-1, are potent myocyte survival factors in vitro (Shengcalcium-handling proteins (Chien et al., 1991). As dis-
played in Figure 4C, both GP CKO and CNT mice display et al., 1996, 1997), but their in vivo function remains
unclear (Wollert and Chien, 1997). Therefore, it becamea greatly enhanced expression of a number of cardiac
genes, including c-fos, brain natriuretic factor (BNP), of interest to determine if the rapid onset of cardiac
dysfunction observed in the GP CKO mice followingsarcoplasmic reticulum Ca21 ATPase (SERCA), ryano-
dine receptor (Ryr), phospholamban (Pln), and inducible TAC was associated with an increase in stress-activated
myocyte apoptosis in these animals. Three independentnitric oxide synthase (iNOS) mRNA following pressure
overload. These data indicate that the loss of gp130 in assays were used to directly compare apoptosis in GP
CKO and CNT hearts 7 days after TAC. As shown inthe heart does not affect the induction of the fetal gene
Cell
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Figure 5. DNA Strand Breaks in Cardiac
Myocyte Nuclei of GP CKO after TAC
(A) DNA laddering of GP CKO cardiac DNA
after TAC. (B) Low power (2003) and (C) high
power (10003) images showing nuclear DNA
labeling visualized by fluorescence (green)
and counterstained with Hoechst dye (blue).
Apoptotic nuclei appear green by TUNEL
staining and demonstrate varying degrees of
condensed nuclear chromatin (arrow).
Figure 5A, a DNA laddering assay revealed evidence of immune system, bone metabolism, neuronal structure
and function, and intermediary metabolism (Taga andan increase in apoptosis in the GP CKO hearts after
TAC. In a second series of experiments, we used a Kishimoto, 1997). Mice that harbor a complete gp130
gene ablation display multiple defects, including hema-TUNEL assay to compare the number of apoptotic car-
diac myocytes in GP CKO and CNT mice after TAC. In topoietic and cardiac defects that ultimately lead to em-
bryonic lethality (Yoshida et al., 1996). In addition, theagreement with the DNA laddering assay, there was
significant increase in apoptotic cells in GP CKO hearts generation of mice that harbor a postnatal deficiency of
gp130 in multiple tissues display a number of defects,(Figure 5B), with apoptotic indices of 34% 6 11% in GP
CKO TAC versus 3% 6 0.5% in CNT mice following TAC including neurological, cardiac, hematopoietic, immu-
nological, hepatic, and pulmonary defects (Betz et al.,(n 5 4 each, p , 0.05). Cells with apoptotic nuclei were
also identified as cardiac myocytes by a-sarcomeric 1998). To a large extent, these widespread effects reflect
their shared use of common gp130 signaling pathwaysactin stain (data not shown) and bisbenzimide (Hoechst
dye 22358) staining. TUNEL-stained nuclei demon- to orchestrate downstream responses in diverse differ-
entiated cell types (Kishimoto et al., 1994). Dissectingstrated varying degrees of condensed nuclear chroma-
tin (Figure 5C), again consistent with a massive induction out which of these phenotypes reflect primary versus
secondary requirements is now possible by controllingof cardiac apoptosis that involved at least one-third of
the ventricular cardiomyocyte population. the spatial onset of the targeting event (Rajewsky et al.,
1996).
Utilizing a knock-in strategy of Cre recombinase intoDiscussion
the endogenous MLC2v gene locus (Chen et al., 1998a,
1998b), we engineered a ventricular restricted knockoutVentricular-Restricted Targeting of the gp130 Gene
Reveals Non±Cardiac Myocyte Cell±Autonomous of the gp130 gene at the earliest stages of ventricular
development. We have now provided clear evidenceRequirement during Normal Cardiac Growth
and Development that the cardiac developmental defects and associated
embryonic lethality do not reflect a requirement of gp130The IL-6 family of cytokines have pleiotropic effects on
multiple organ systems, including hematopoiesis, the pathways in cardiac myocytes per se. The most likely
GP130 Myocyte Survival Pathways and Heart Failure
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explanation is that the cardiac defects and thinning of In this regard, the present study provides clear evi-
the ventricular chamber wall that resembles a number dence that gp130 is part of an essential stress-activated
of other cardiac embryonic lethal mutations, arises sec- myocyte survival pathway. While there is no apparent
ondary to the hematopoietic defect and associated oxy- requirement for gp130 in the normal physiological re-
gen deprivation. Interestingly, the gp130 pathway also sponse of the heart, gp130 pathways are rapidly acti-
does not appear to be required for normal heart growth vated in response to the mechanical stress of pressure
in the postnatal setting. overload. Following thoracic aortic constriction, there is
This distinction between a primary and secondary re- a marked increase in cardiac mortality, such that almost
quirement for a discrete signaling pathway has been none of the ventricular-restricted gp130 knockout mice
shown to be particularly important with respect to the survive past 7 days following imposition of a 35 mm
growing number of mice that harbor defects in cardiac pressure transaortic gradient. Within 3±4 days of aortic
chamber morphogenesis and that also die as a result banding, the gp130 ventricular restricted knockout mice
of embryonic heart failure (for a review, see Fishman display a rapid onset of dilated cardiomyopathy, which
and Chien, 1997). For example, previous studies have is accompanied by massive myocyte apoptosis, involv-
shown that the retinoid receptor RXRa is responsible ing over 30% of the ventricular myocytes. Taken to-
for the vitamin A signaling pathways that are required gether, these studies provide evidence that gp130 medi-
to maintain normal cardiac morphogenesis (Kastner et ates a myocyte survival pathway that acts to block the
al., 1994; Sucov et al., 1994; Dyson et al., 1995; Gruber onset of myocyte apoptosis during pressure overload.
et al., 1998). Mice that harbor a complete ablation of In this manner, mechanical stimuli may activate not only
the RXRa gene display all of the features of vitamin pathways that promote myocyte apoptosis, but also
A deficiency, including defects in neural crest±related may concomitantly activate myocyte survival pathways.
defects in the outflow tract, atrioventricular cushion Recently, our laboratory has obtained additional evi-
defects (Gruber et al., 1996), and severe ventricular dence in vitro that cardiac myocyte apoptosis and hy-
muscle defects that result in marked thinning of the pertrophy may be activated by common signaling path-
ventricular chamber wall and secondary embryonic ways. This work emanates from previous studies, which
heart failure with associated in vivo cardiac dysfunction eventually resulted in the identification and cloning of
(Ruiz-Lozano et al., 1998). However, recent studies based
CT-1 (Pennica et al., 1995), a novel cardiac cytokine
on mice that harbor a ventricular restricted knockout of
that was cloned from an embryonic stem cell in vitro
the RXRa gene have indicated that all of these defects
cardiogenesis model system (Miller-Hance et al., 1993).do not reflect a requirement for RXRa in ventricular mus-
Utilizing expression cloning technology, CT-1 was iden-cle cells per se, but rather reflect a requirement from
tified as a novel agent to promote cardiac myocyte hy-another cardiac cellular compartment, most likely via a
pertrophy in a high-throughput in vitro neonatal rat myo-paracrine pathway (Chen et al., 1998b). Thus, the cardiac
cardial cell assay system (Pennica et al., 1995). Themuscle defects that are related to embryonic lethality
structure of CT-1 indicated that it was a member of thedo not reflect an intrinsic requirement for RXRa in heart
IL-6 family that operates through the common signal-muscle, and the muscle defect is related to a secondary
transducing membrane receptor gp130 (for review, seeeffect. Taken together with the results of the current
Wollert and Chien, 1997). Subsequent studies from ourstudy, the ªthin wallº myocardial defect seen in a wide
laboratory documented that a gp130-LIF receptor b het-number of gene-targeted embryos may likely indicate a
erodimer constituted the CT-1 receptor on the surfacesecondary as opposed to a primary defect of the tar-
of cardiac myocytes (Wollert et al., 1996), and that sub-geted gene.
sequent activation of JAK and STAT3 were responsible
for the induction of a hypertrophic response and activa-Biomechanical Stress Activates a gp130
tion of a panel of embryonic genes (Sheng et al., 1996,Cardiomyocyte Survival Pathway
1997). In subsequent studies, we documented that CT-1Biomechanical stress during chronic increases in blood
could promote cardiac myocyte survival of both embry-pressure and circulatory volume is a major determinant
onic and neonatal cardiac muscle cells (Sheng et al,of cardiac function and the transition to heart muscle
1996, 1997). These studies support the concept that thefailure. In response to mechanical overload, the heart
genetic ablation of the gp130 receptor and the subse-activates an adaptive physiological response of cardiac
quent crippling of myocyte survival patterns in vivo aremuscle hypertrophy, that acts to increase muscle mass
due to a direct effect of gp130-dependent ligands onand to maintain normal cardiac function (Chien et al.,
ventricular cardiomyocytes. Taken together with the re-1998). As a result, the onset of chamber dilation, cardio-
sults of the present study, we conclude that myocytemyopathy, and overt heart failure are usually only seen
survival pathways and the corresponding blockade ofafter months or years of chronic exposure to the initiat-
myocyte apoptosis may be critical in the onset of com-ing bioimechanical stimulus (e.g., high blood pressure,
pensatory cardiac hypertrophy versus the transition tovalvular disease, and postmyocardial infarction). The
heart failure. Based on the current and previous studies,identification of the precise signaling pathways that me-
a working model can be proposed whereby biomechani-diate this stress-activated response is one of the most
cal stress induces hypertrophic signals (Ras, Gq, p38b,important questions in cardiovascular biology and medi-
others) (Thorburn et al., 1993; LaMorte et al., 1994; Gott-cine (Chien, 1993). Of particular importance would be
shall et al., 1997; Wang et al., 1998a) and apoptoticthe identification of genetic modifiers of the response
signals (Gq, p38a, others) (Adams et al., 1998; Wang etthat act to promote or suppress the onset of the heart
al., 1998a, 1998b) that represent two distinct phenotypicfailure phenotype in the setting of exposure to biome-
outcomes. At the same time, biomechanical signals leadchanical stress. Such pathways could become impor-
to the release of gp130 ligands that activate a myocytetant targets for the development of new therapeutic
strategies for heart failure. survival pathway, shifting the balance toward adaptive
Cell
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Figure 6. The Proposed Role of gp130 Sig-
naling Pathways in the Transition between
Cardiac Hypertrophy and Heart Failure in Re-
sponse to Biomechanical Stress
Biomechanical stress activates multiple par-
allel and converging signals for hypertrophy
and apoptosis that represent two distinct
phenotypic outcomes (for a review, see Chien
et al., 1998). At the same time, biomechanical
stress also leads to the induction of gp130-
dependent ligands, resulting in the activation
of downstream gp130 pathways that act to
block the actions of proapoptotic pathways.
In the absence of gp130, the cardiac myocyte
response to biomechanical stress is shifted
toward cell death, resulting in the loss of func-
tional myocytes and the onset of heart failure.
Thus, the phenotypic outcome of biomechan-
ical stress is dependent on the balance be-
tween the contradictory signal transduction
pathways.
hypertrophy. In this regard, semiquantitative RT-PCR of critical interest. Given the importance of STAT3 in in
vitro function of CT-1, the question arises as to whetherdocumented that LIF was significantly increased (p ,
0.05) in the heart 2 days after TAC (data not shown). In all of the gp130-dependent survival effect is mediated
via STAT3 pathways. The possibility exists that modifi-the absence of the gp130 signaling pathway in the heart,
there is an acceleration of this transition to heart failure cation of gp130-mediated myocyte survival pathways
represents a novel therapeutic strategy for promotingthat most likely occurs through an unopposed effect of
apoptotic pathways in the setting of chronic mechanical and maintaining cardiac myocyte function in response
to acute mechanical and/or other stress-induced stimulistress (Figure 6).
(e.g., hypoxia, adriamycin, etc.). The availability of this
engineered mouse model should prove useful in theThe Loss of Myocyte Survival Is Critical in the
Transition to Dilated Cardiomyopathy identification of new downstream targets for promoting
in vivo cardiac myocyte survival and preventing the tran-and Heart Failure
Recent studies have documented that apoptosis can sition to heart failure during biomechanical stress.
occur in the setting of cardiac hypertrophy and failure
Experimental Proceduresin both experimental model systems and in the setting
of human congestive heart failure (for review, see Haun-
In Vivo Physiological Assaysstetter and Izumo, 1998). However, the extent to which
Breeding and identification of crosses between MLC2vCre and
apoptosis plays a critical role in the transition between gp130 floxed allele mice was performed as previously described
compensatory hypertrophy and overt cardiac failure has (Chen et al., 1998b). Transthoracic echocardiography (Tanaka et. al.,
1996), hemodynamic evaluation (Arber et al., 1997), and transversebeen an open question, due to the difficulty of scoring
aortic constriction (Rockman et al., 1991) was performed as pre-for myocyte apoptosis, which can be an infrequent event
viously described.even in the setting of cardiac hypertrophy and heart
failure. In addition, scoring for the event at an individual
Isolation of Cardiac Myocyte
cell level has also been problematic, as well as a means Adult ventricular cells were isolated by retrograde perfusion with
to specifically quantitate the rate and extent of apopto- collagenase and two sequential 6% BSA gradients by a modification
(Chen et al., 1998b) previously described (Wolska and Solaro, 1996).sis in cardiac myocytes per se, as opposed to infiltrating
cardiac muscle cells or nonmyocytes that comprise the
Western and Northern Blot Analysismajority of cell types within the heart.
Western blot analysis was performed utilizing rabbit polyclonal anti-The results of the current study provide the strongest
bodies to gp130, STAT3 (Santa Cruz), and phospho-specific STAT3
evidence to date that myocyte apoptosis is a critical (New England Biolabs Inc.). Horseradish peroxidase-conjugated
event in the transition to heart failure. Thus, the inhibition anti-rabbit immunoglobulin G was used for detection (Santa Cruz).
Northern blotting was performed as previously described (Rockmanof cardiac myocytes apoptosis is now clearly a valid
et al., 1991).target for the development of new therapeutic agents
for cardiac heart failure. As noted earlier, our working
Apoptosis Assay
model suggests that, under normal circumstances, the For internucleosomal DNA cleavage assays, DNA preparation and
myocyte survival pathways can effectively blunt the on- agarose electrophoresis were performed essentially as described
set of myocyte apoptosis in response to biomechanical (Teiger et al., 1996; Olivetti et al., 1997; Haunstetter and Izumo,
1998). For the terminal deoxytransferase assay (TUNEL), we usedstress, leading to the induction of compensatory hyper-
the Apoptag kit (Oncor) for in situ apoptosis detection.trophy (see Figure 6). However, at a later point in time,
this balance has tipped, such that there is a transition
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